DEXCOM, INC.
Surgical & Medical Instruments & Apparatus- 売上
- $4.7bn
- 時価総額
- $29.1bn
株価 $74.54 · 100株 7,454円
| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $3.6bn | $4.0bn | $4.7bn |
| 成長率 | — | 11.3% | 15.6% |
| 総利益 | $2.3bn | $2.4bn | $2.8bn |
| 総利益率 | 63.2% | 60.5% | 60.1% |
| 販管費 | $1.2bn | $1.3bn | $1.3bn |
| 販管費率 | 32.7% | 31.9% | 27.7% |
| 営利 | $598m | $600m | $912m |
| 営利率 | 16.5% | 14.9% | 19.6% |
| 純利益 | $542m | $576m | $836m |
| PBR | 14.1 | 13.9 | 10.6 |
| PSR | 8.0 | 7.2 | 6.2 |
| PGPR | 12.7 | 11.9 | 10.4 |
| PER | 54 | 51 | 35 |
| ネットキャッシュ | $498m | $537m | $853m |
| EV/EBITDA | 36.5 | 35.0 | 24.3 |
| Rule of 40 | — | 26% | 35% |
| セールス効率 | — | 149% | 6,994% |
※Rule of 40は売上成長率+営業利益率、セールス効率は売上総利益増加÷販管費増加(販管費増のときのみ)
